Infliximab
- Generic Name
- Infliximab
- Brand Names
- Avsola, Flixabi, Inflectra, Remicade, Renflexis, Zessly, Remsima
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 170277-31-3
- Unique Ingredient Identifier
- B72HH48FLU
- Background
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammato...
- Indication
用于治疗：
⑴类风湿性关节炎：本品常与甲氨蝶呤合用于中重度活动性类风湿性关节炎；
⑵克罗恩病及瘘管性克罗恩病；
⑶强直性脊柱炎等自身免疫性疾病，以减轻症状和体征，改善身体机能，预防患者残疾。
⑷用于银屑病关节炎的治疗【美国FDA已批准；英国风湿病学会/英国风湿病卫生专业人员协会《BSR／BHPR—应用生物制剂治疗银屑病关节炎指南》2012版；欧洲抗风湿病联盟《EULAR—银屑病关节炎药 物治疗管理建议》2011版
】。
⑸用于6岁及以上儿童溃疡性结肠炎的治疗【美国FDA已批准；中华医学会内科学会《炎症性肠病诊断与治疗的共识意见》；中华医学会消化病学分会炎症性肠病学组《英夫利西治疗克罗恩病的推荐方案（2011年】。
- Associated Conditions
- Ankylosing Spondylitis (AS), Chronic Plaque Psoriasis, Fistulizing Crohn's Disease, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Rheumatoid Arthritis, Moderately to Severely Active Ulcerative Colitis, Pediatric Crohn’s Disease, Psoriatic Arthritis
- Associated Therapies
- -
Treatment of Refractory Diabetic Macular Edema With Infliximab
- Conditions
- Interventions
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2009-02-20
- Lead Sponsor
- University of Athens
- Target Recruit Count
- 12
- Registration Number
- NCT00505947
- Locations
- 🇬🇷
Medical School, University of Athens, Athens, Greece
🇬🇷University of Athens, Athens, Greece
A Study of Infliximab for Treatment Resistant Major Depression
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Emory University
- Target Recruit Count
- 60
- Registration Number
- NCT00463580
- Locations
- 🇺🇸
Emory Clinic, Emory University Hospital, Atlanta, Georgia, United States
Centocor Microarray Study of Patients
- Conditions
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 31
- Registration Number
- NCT00462072
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Treatment With TNF Blockade, Infliximab, in Patients With Myositis
- Conditions
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2007-03-05
- Lead Sponsor
- Karolinska Institutet
- Registration Number
- NCT00443222
Study of Two Schedules of Infliximab Maintenance Therapy in Ankylosing Spondylitis
- Conditions
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2007-02-27
- Target Recruit Count
- 240
- Registration Number
- NCT00439283
- Locations
- 🇫🇷
CHU Amiens, Amiens, France
🇫🇷CHU Hôpital Minjoz, Besançon, France
🇫🇷Hôpital Gilles de Corbeil, Corbeil Essonnes, France
Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2009-03-11
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 40
- Registration Number
- NCT00432406
- Locations
- 🇨🇳
Prince of Wales Hospital, Hong Kong, China
TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )
- Conditions
- Interventions
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2009-10-05
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 1
- Registration Number
- NCT00368264
- Locations
- 🇩🇪
Internal Medicine III, University of Erlangen, Erlangen, Germany
🇦🇹Internal Medicine II, Hietzing Hospital, Vienna, Austria
🇩🇪Rheumatology, Charite, Berlin, Germany
Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease
- Conditions
- Interventions
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2015-12-29
- Target Recruit Count
- 40
- Registration Number
- NCT00325078
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
- Conditions
- Interventions
- First Posted Date
- 2006-03-28
- Last Posted Date
- 2007-11-19
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 20
- Registration Number
- NCT00307593
- Locations
- 🇫🇷
Hôpital Cochin, Paris, France
Use of Infliximab for the Treatment of Pemphigus Vulgaris
- First Posted Date
- 2006-01-30
- Last Posted Date
- 2017-12-06
- Target Recruit Count
- 20
- Registration Number
- NCT00283712
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸Norris Cancer Center, University of Southern California, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.